Promising Phase 3 Data Could Propel Candel Therapeutics

AI Prediction of Candel Therapeutics, Inc. (CADL)

Candel Therapeutics is poised for potential growth with upcoming clinical and regulatory catalysts that could significantly influence its stock price.
Candel Therapeutics, a clinical-stage biopharmaceutical company, is focused on developing viral immunotherapies for cancer treatment. Its lead assets, aglatimagene besadenovec and linoserpaturev, target various cancers including prostate cancer and NSCLC. Key upcoming catalysts include the presentation of Phase 3 prostate cancer data and initiation of a Phase 3 trial for NSCLC. These events, coupled with a strengthened balance sheet and recent financial maneuvers to secure funding into Q1 2028, position the company in a potentially advantageous market position. Successful outcomes in these trials could lead to significant price movement due to the high unmet medical needs and substantial market sizes of the targeted indications.

 

CADL Report Information

Prediction Date
  • 2026-03-18
    • Close @ Prediction
  • $5.17
    • Mkt Cap
  • 1000m
    • IPO Date
  • N/a

    • AI-derived Information

    Premium Content

    This section is available to members. Log in or sign up to see full predictions.

    Recent News for CADL

    Open full-screen chart with Ext Hrs


    Welcome to ScanScor. What you're reading is no ordinary summary -- it's the result of a carefully-crafted interactive session with OpenAI's most advanced models crafted from news, trial details, and financial data. This report attempts to maximize the potential for OpenAI's smartest GPT-based analysis engine, guided by tightly structured prompts to expose the forces behind today's market movers and to predict the future.

    Disclaimer: This report is for informational purposes only. It does not constitute financial advice. Always do your own research before making any investment.

    0 0 votes
    Article Rating
    Subscribe
    Notify of
    0 Comments
    Oldest
    Newest Most Voted
    Scroll to Top
    0
    Would love your thoughts, please comment.x
    ()
    x